PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29970185-0	2018	Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.	Azithromycin	0-12	TNF receptor superfamily member 10a	Homo sapiens	115-120	
29970185-13	2018	Azithromycin increased the expressions of DR4, DR5, p62 and LC-3B proteins and potentiated induction of apoptosis by TRAIL.	Azithromycin	0-12	TNF receptor superfamily member 10a	Homo sapiens	42-45	
29970185-16	2018	CONCLUSION: The synergistic antitumor effect of azithromycin and TRAIL mainly relies on the up-regulations of DR4 and DR5, which in turn result from LC-3B-involved autophagy inhibition.	Azithromycin	48-60	TNF receptor superfamily member 10a	Homo sapiens	110-113	
29970185-14	2018	Knockdown of DR4 and DR5 with siRNAs increased cell survival rate and decreased the expression of cleaved-PARP induced by the combination of azithromycin and TRAIL.	Azithromycin	141-153	TNF receptor superfamily member 10a	Homo sapiens	13-16